Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) EBITDA Margin (2024)

Zentalis Pharmaceuticals has reported EBITDA Margin over the past 1 years, most recently at 185.55% for Q4 2024.

  • Quarterly results put EBITDA Margin at 185.55% for Q4 2024, changed N/A from a year ago — trailing twelve months through Sep 2025 was 615.16% (down 9922.0% YoY), and the annual figure for FY2024 was 283.57%, changed.
  • EBITDA Margin for Q4 2024 was 185.55% at Zentalis Pharmaceuticals, down from 61.06% in the prior quarter.
  • Over the last five years, EBITDA Margin for ZNTL hit a ceiling of 61.06% in Q1 2024 and a floor of 185.55% in Q4 2024.